Lactic acid bacterium growth enhancer, regulatory T-cell number increasing agent, method of enhancing growth of lactic acid bacterium, method of increasing number of regulatory T-cells, method of evaluating regulatory T-cell number increasing effect, and method of evaluating lactic acid growth enhancing effect

Patent metadata

Field	Value
Publication number	US-9738731-B2
Application number	US-201414772839-A
Country	US
Kind code	B2
Filing date	Mar 10, 2014
Priority date	Mar 8, 2013
Publication date	Aug 22, 2017
Grant date	Aug 22, 2017

Abstract

A growth enhancer for Lactobacillus murinus, Lactobacillus salivarius , or a bacterium that belongs to the genus Lactobacillus and that has a homology of 16S rDNA of 90% or higher with Lactobacillus murinus or Lactobacillus salivarius includes a β-glucan having a molecular weight of from 0.2 K to 50 K. A regulatory T-cell number increasing agent, a method of enhancing growth of a lactic acid bacterium, a method of increasing the number of regulatory T-cells, a method of evaluating a regulatory T-cell number increasing effect, and a method of evaluating a growth enhancing effect on a lactic acid bacterium are also provided.

First claim

The invention claimed is:

1. A method of increasing a number of regulatory T-cells in a subject, comprising orally administering a β-glucan having a molecular weight of from 0.2 K to 50 K to the subject, wherein the subject comprises Lactobacillus murinus, Lactobacillus salivarius , or a bacterium that belongs to the genus Lactobacillus , has a homology of 16S rDNA of 95% or higher with at least one of Lactobacillus murinus or Lactobacillus salivarius.

2. The method according to claim 1 , wherein the β-glucan has a molecular weight of from 1 K to 10 K.

3. The method according to claim 1 , wherein the β-glucan comprises a β-1,3-glucan.

4. A method of evaluating a regulatory T-cell number increasing effect, the method comprising:
analyzing microbiota of a sample collected from a subject to which a β-glucan having a molecular weight of from 0.2 K to 50 K has been administered; and
determining a ratio of Lactobacillus murinus, Lactobacillus salivarius , or a bacterium that belongs to the genus Lactobacillus , has a homology of 16S rDNA of 95% or higher with at least one of Lactobacillus murinus or Lactobacillus salivarius to all bacteria in the microbiota, and has an activity of up-regulating regulatory T-cells.

5. The method according to claim 4 , further comprising:
analyzing microbiota of a sample collected from the subject before the administration of the β-glucan and determining a ratio of Lactobacillus murinus, Lactobacillus salivarius , or a bacterium that belongs to the genus Lactobacillus , has a homology of 16S rDNA of 95% or higher with at least one of Lactobacillus murinus or Lactobacillus salivarius to all bacteria in the microbiota, and has an activity of up-regulating regulatory T-cells.

6. The method according to claim 1 , wherein the subject is in need of an increase in the number of regulatory T-cells.

7. The method according to claim 1 , wherein the subject suffers from an inflammatory or allergic disease or symptom, and the inflammatory or allergic disease or symptom is treated or ameliorated by the administration of the β-glucan via an increase in the number of regulatory T-cells in the subject.

8. The method according to claim 7 , wherein the inflammatory or allergic disease or symptom is an inflammatory bowel disease, a food allergy or pollinosis.

9. The method according to claim 8 , wherein the inflammatory bowel disease is Ulcerative colitis or Crohn's disease.

10. The method according to claim 1 , wherein the inflammatory or allergic disease or symptom is prevented by the administration of the β-glucan via an increase in the number of regulatory T-cells in the subject.

11. The method according to claim 10 , wherein the inflammatory or allergic disease or symptom is an inflammatory bowel disease, a food allergy or pollinosis.

12. The method according to claim 11 , wherein the inflammatory bowel disease is Ulcerative colitis or Crohn's disease.

13. The method according to claim 4 , wherein the β-glucan has a molecular weight of from 1 K to 10 K.

14. The method according to claim 4 , wherein the β-glucan comprises a β-1,3-glucan.

15. A method of increasing a number of regulatory T-cells in a subject, comprising: orally administering a β-glucan having a molecular weight of from 0.2 K to 50 K in an amount sufficient for enhancing growth of Lactobacillus murinus, Lactobacillus salivarius , or a bacterium that belongs to the genus Lactobacillus , has a homology of 16S rDNA of 95% or higher with at least one of Lactobacillus murinus or Lactobacillus salivarius to the subject; and
allowing the Lactobacillus murinus , the Lactobacillus salivarius , or the bacterium that belongs to the genus Lactobacillus , has a homology of 16S rDNA of 95% or higher with at least one of Lactobacillus murinus or Lactobacillus salivarius to exert an effect with respect to increasing the number of regulatory T-cells in the subject.

Assignees

• Univ Tokyo Science Found

Inventors

• Iwakura Yoichiro
• Tang ce
• Ohno Naohito

Classifications

• A61P37/08

  Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14) · CPC title

• A61P29/00

  Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] · CPC title

• C12Q1/025

  for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics (antimicrobial activity C12Q1/18) · CPC title

• G01N2333/335

  from Lactobacillus (G) · CPC title

• G01N33/505

  involving T-cells · CPC title